{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:26:32Z","timestamp":1766157992155,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.diagmicrobio.2016.11.019","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T08:32:46Z","timestamp":1480408366000},"page":"261-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antimicrobial activity of ceftazidime\u2013avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013\u20132014)"],"prefix":"10.1016","volume":"87","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Avycaz\u00ae","key":"10.1016\/j.diagmicrobio.2016.11.019_bb0005"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 x '20 progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jac\/dks512","article-title":"There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy","volume":"68","author":"Bow","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","article-title":"A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant gram-negative pathogens","volume":"46","author":"Bush","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0025","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"year":"2015","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2016.11.019_bb0030"},{"year":"2016","series-title":"M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2016.11.019_bb0035"},{"author":"EUCAST","key":"10.1016\/j.diagmicrobio.2016.11.019_bb0040"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0050","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1378\/chest.14-2171","article-title":"Antimicrobial resistance in hospital-acquired gram-negative bacterial infections","volume":"147","author":"Mehrad","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","article-title":"The current spectrum of infection in cancer patients with chemotherapy related neutropenia","volume":"42","author":"Nesher","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0070","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0075","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00277-014-2086-0","article-title":"Management of sepsis in neutropenic patients: 2014 updated guidelines from the infectious diseases working Party of the German Society of hematology and medical oncology (AGIHO)","volume":"93","author":"Penack","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0080","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0085","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"year":"2016","series-title":"Tygacil \u00ae package insert","author":"Tygacil","key":"10.1016\/j.diagmicrobio.2016.11.019_bb0090"},{"key":"10.1016\/j.diagmicrobio.2016.11.019_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316304023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316304023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:27:34Z","timestamp":1536226054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316304023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0732889316304023"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.11.019","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of ceftazidime\u2013avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013\u20132014)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}